Cytek BioSciences Profit Margin

The latest profit margin for CTKB is -38.98% as of June 2026. That compares with -3.27% in the prior-year period — down 1093.8% year over year. That is below the Healthcare sector average of 13.76%. Investors often review this figure alongside Cytek BioSciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CTKB's profit margin moved from -3.27% to -38.98% — a 1093.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cytek BioSciences's valuation or profitability profile.

Against Healthcare companies, CTKB currently prints -38.98% for profit margin, while the sector average sits near 13.76%. That is roughly 383.3% below the sector mean. Large gaps often invite a closer look at Cytek BioSciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Cytek BioSciences converts resources into returns. At -38.98%, CTKB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -3.27% in the prior-year period — down 1093.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CTKB's profit margin (-38.98%), review year-over-year change from -3.27%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.